ABVC BioPharma, Inc.
ABVC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $510 | $152 | $970 | $356 |
| % Growth | 234.3% | -84.3% | 172.6% | – |
| Cost of Goods Sold | $1 | $302 | $286 | $5 |
| Gross Profit | $509 | -$150 | $683 | $351 |
| % Margin | 99.9% | -98.1% | 70.5% | 98.6% |
| R&D Expenses | $179 | $1,063 | $2,693 | $1,004 |
| G&A Expenses | $5,035 | $5,554 | $13,104 | $11,053 |
| SG&A Expenses | $5,035 | $5,554 | $13,104 | $11,053 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5,214 | $6,617 | $15,798 | $12,057 |
| Operating Income | -$4,705 | -$6,767 | -$15,114 | -$11,706 |
| % Margin | -923.3% | -4,439.2% | -1,558.5% | -3,290.1% |
| Other Income/Exp. Net | -$664 | -$1,258 | -$400 | $495 |
| Pre-Tax Income | -$5,370 | -$8,025 | -$15,515 | -$11,211 |
| Tax Expense | -$111 | $256 | $798 | $825 |
| Net Income | -$4,903 | -$7,788 | -$16,423 | -$12,839 |
| % Margin | -962.1% | -5,109.3% | -1,693.5% | -3,608.5% |
| EPS | -0.42 | -1.8 | -5.2 | -5.1 |
| % Growth | 76.7% | 65.4% | -2% | – |
| EPS Diluted | -0.42 | -1.8 | -5.2 | -5.1 |
| Weighted Avg Shares Out | 11,674 | 4,336 | 3,166 | 2,505 |
| Weighted Avg Shares Out Dil | 11,674 | 4,336 | 3,166 | 2,505 |
| Supplemental Information | – | – | – | – |
| Interest Income | $87 | $185 | $188 | $43 |
| Interest Expense | $826 | $1,314 | $294 | $227 |
| Depreciation & Amortization | $201 | $380 | $24 | $12 |
| EBITDA | -$4,343 | -$6,331 | -$15,197 | -$10,972 |
| % Margin | -852.2% | -4,153.2% | -1,567% | -3,083.7% |